Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Obesity matters for drug developers
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%. The R&D pipeline is filling up as more and more companies try to grab a slice of this…
Report library
Q3 Round up: Alive but not kicking infographic
In this quarterly snapshot, we highlight financial and business trends in biopharma. Download our Q3 Roundup infographic now for our quick take on M&A activity, the…
Intelligent forecasting for pharmaceutical R&D
Commercial analytics and forecasting underpin strategic decision-making and business planning across the pharmaceutical and life science sectors. Inaccurate risk…
The Impact of Data Science
Digital technologies have plenty to offer a pharma industry seeking to up its productivity game. Attention often focuses artificial intelligence powered drug discovery or…
World Preview 2022: Outlook to 2028 Report
After a 27-month rollercoaster ride, can we expect a return to normal? Battered biotech is reviving after booming and busting in spectacular fashion. M&A is…
World Preview: Patents and Pricing Infographic
Our annual World Preview infographic provides forward-looking analysis of the pharma and biotech market, based on Evaluate consensus forecasts to 2028. The top…
ESMO 2022 eBook
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce…
Medtech World Preview 2022: Back to Reality Report
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid…
Medtech World Preview 2022: Back to Reality Infographic
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic…
PD(L)anner – September 2022
Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…
Medtech Infographic: The only way is up - or is it?
As we venture into the second half of 2022, has the medtech market hit its lowest ebb? Will the slump continue or are there a few flickers of light on the horizon, if you…
